Evidence map›Paper›PMID 40406094›Full record

ReviewFrontiers in immunology2025

Microbiota as diagnostic biomarkers: advancing early cancer detection and personalized therapeutic approaches through microbiome profiling.

Majid Eslami, Ramtin Naderian, Aisa Bahar, Ali Babaeizad, Solaleh Rezanavaz Gheshlagh, Valentyn Oksenych, Hamed Tahmasebi

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Microbiome-guided cancer immunotherapy: immune mechanisms, resistance pathways, and translational opportunities for precision oncology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. The dual roles ofFrontiers in oncology · 2026
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Majid EslamiCancer Research Center, Semnan University of Medical Sciences, Semnan, Iran.
Ramtin NaderianClinical Research Development Unit, Kowsar Educational, Research and Therapeutic Hospital, Semnan University of Medical Sciences, Semnan, Iran.
Aisa BaharDepartment of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Ali BabaeizadStudent Research Committee, Semnan University of Medical Sciences, Semnan, Iran.
Solaleh Rezanavaz GheshlaghStudent Research Committee, Semnan University of Medical Sciences, Semnan, Iran.
Valentyn OksenychFaculty of Medicine, University of Bergen, Bergen, Norway.
Hamed TahmasebiSchool of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The important function of microbiota as therapeutic modulators and diagnostic biomarkers in cancer has been shown by recent developments in microbiome research. The intricate interplay between the gut microbiota and the development of cancer, especially in colorectal and breast cancers, emphasizes how microbial profiling may be used for precision treatment and early diagnosis. Important microbial signatures, including

Indexed as

Biomarkers, TumorEarly Detection of CancerGastrointestinal MicrobiomeNeoplasmsAnimalsFecal Microbiota TransplantationHumansPrecision MedicineBiomarkers, Tumorbiomarkerscancermicrobiome profilingmicrobiotapersonalized medicine

Identifiers

PMID40406094
PMCPMC12095362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.